Zobrazeno 1 - 10
of 459
pro vyhledávání: '"Jens Huober"'
Autor:
Bruno Valentin Sinn, Katharina Sychra, Michael Untch, Thomas Karn, Marion van Mackelenbergh, Jens Huober, Wolfgang Schmitt, Frederik Marmé, Christian Schem, Christine Solbach, Elmar Stickeler, Hans Tesch, Peter A. Fasching, Andreas Schneeweiss, Volkmar Müller, Johannes Holtschmidt, Valentina Nekljudova, Sibylle Loibl, Carsten Denkert
Publikováno v:
Breast Cancer Research, Vol 26, Iss 1, Pp 1-11 (2024)
Abstract Background Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better outcomes, potentially warranting less extensive surgical and systemic treatments. Early prediction of treatme
Externí odkaz:
https://doaj.org/article/7254adee1eef456f91cca8c6f84490e2
Autor:
Volker Möbus, Hans-Joachim Lück, Ekkehart Ladda, Peter Klare, Knut Engels, Marcus Schmidt, Andreas Schneeweiss, Eva-Maria Grischke, Grischa Wachsmann, Helmut Forstbauer, Michael Untch, Frederik Marmé, Jens-Uwe Blohmer, Christian Jackisch, Jens Huober, Elmar Stickeler, Mattea Reinisch, Theresa Link, Bruno Sinn, Wolfgang Janni, Carsten Denkert, Sabine Seiler, Christine Solbach, Sabine Schmatloch, Julia Rey, Sibylle Loibl
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)
Abstract GAIN-2 trial evaluated the optimal intense dose-dense (idd) strategy for high-risk early breast cancer. This study reports the secondary endpoints pathological complete response (pCR) and overall survival (OS). Patients (n = 2887) were rando
Externí odkaz:
https://doaj.org/article/b93eb5cc3e364be681372848cc75b63c
Autor:
Matthew P. Goetz, Irfan Cicin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen R. D. Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to p
Externí odkaz:
https://doaj.org/article/1378a75d34cd4a89ad1255e30c08bb59
Autor:
Chiara Massa, Thomas Karn, Karsten Weber, Andreas Schneeweiss, Claus Hanusch, Jens Uwe Blohmer, Dirk‐Michael Zahm, Christian Jackisch, Marion van Mackelenbergh, Jörg Thomalla, Frederik Marmé, Jens Huober, Volkmar Müller, Christian Schem, Anja Müller, Elmar Stickeler, Katharina Biehl, Peter A. Fasching, Michael Untch, Sibylle Loibl, Carsten Denkert, Barbara Seliger
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 4, Pp n/a-n/a (2024)
Externí odkaz:
https://doaj.org/article/f921f7466a0a4b568dfafa8ea0d35cf6
Autor:
Jens Huober, Marion van Mackelenbergh, Andreas Schneeweiss, Fenja Seither, Jens-Uwe Blohmer, Carsten Denkert, Hans Tesch, Claus Hanusch, Christoph Salat, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Christian Jackisch, Mattea Reinisch, Bianca Lederer, Keyur Mehta, Theresa Link, Valentina Nekljudova, Sibylle Loibl, Michael Untch
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-12 (2023)
Abstract This retrospective pooled analysis aims to identify factors predicting relapse despite a pathologic complete response (pCR) in patients with breast cancer (BC). 2066 patients with a pCR from five neoadjuvant GBG/AGO-B trials fulfill the incl
Externí odkaz:
https://doaj.org/article/1894262e05954747a7b2989d697dd085
Autor:
Cornelia Leo, Kathrin Schwedler, Rosaria Condorelli, Nicole Bürki, Jens Huober, Khalil Zaman, Christian Kurzeder, Marcus Vetter
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 17, Iss 3 (2023)
Information on germline BRCA (g*BRCA*) 1/2 pathogenic or likely pathogenic mutations has predictive value for response to platinating agents and poly(ADP-ribose) polymerase inhibitors (PARPi) and survival outcomes of breast cancer (BC) patients. In t
Externí odkaz:
https://doaj.org/article/cf049c079418491f9bbe809dabc7ebb9
Autor:
Norbert Gelse, Daniela Bodschwinna, Marc N. Jarczok, Magdalena Wanner, Madeleine Volz, Regine Mayer-Steinacker, Jens Huober, Harald Gündel, Klaus Hönig
Publikováno v:
Frontiers in Psychology, Vol 14 (2023)
IntroductionPsycho-oncological interventions can reduce distress by activating individual resources and enhancing coping skills. Since medical cancer treatment is performed increasingly in outpatient settings, there is a growing need for evidence-bas
Externí odkaz:
https://doaj.org/article/5177523237d74a2ba7380349232f8ff6
Autor:
Shani Paluch-Shimon, Patrick Neven, Jens Huober, Irfan Cicin, Matthew P. Goetz, Chikako Shimizu, Chiun-Sheng Huang, Hans Joachim Lueck, Jane Beith, Eriko Tokunaga, Jessica Reyes Contreras, Rosane Oliveira de Sant’Ana, Ran Wei, Ashwin Shahir, Sarah C. Nabinger, Tammy Forrester, Stephen R. D. Johnston, Nadia Harbeck
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), node-positive, and high-risk ear
Externí odkaz:
https://doaj.org/article/9dbf86693a4a460dbf6601907c6ba0ed
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 3, Iss 1, Pp 27-36 (2022)
Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characteristics. ADCs represent a class of therapeutics that com
Externí odkaz:
https://doaj.org/article/555f1ecf6e8244a0b551fa828bf51f4f
Autor:
Inga Bekes, Jens Huober
Publikováno v:
Cancers, Vol 15, Iss 16, p 4190 (2023)
Seventy percent of all breast cancer subtypes are hormone receptor-positive. Adjuvant endocrine therapy in these patients plays a key role. Despite the traditional duration of a 5-year intake, the risk of relapse remains elevated in a substantial pro
Externí odkaz:
https://doaj.org/article/1cfef188016841a9bc9657d8754b4a35